Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab versus standard predniso(lo)ne taper for adults with de novo minimal change disease
2025-520641-69-00Phase 2Authorised
- Sponsor
- Medical University of Innsbruck
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised trial of obinutuzumab and prednisolone in nephrosis (2 arms), sponsored by Medical University of Innsbruck. Primary endpoints: Non-inferiority of obinutuzumab to standard predniso(lo)ne taper and Superiority of obinutuzumab for sustained remission and relapse prevention. Planned start Jul 2026; status: authorised.
02
Drugs
obinutuzumabprednisolone
03
Conditions
nephrosis
Beyond the preview
Go deeper on 2025-520641-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520641-69-00.